Baseline SII and SIRI identify immune-inflammatory susceptibility and improve risk stratification of early subclinical cardiac dysfunction during non-steroidal aromatase inhibitor therapy
Source check: Source checked. Not independent scientific confirmation.
Finding: In a single-center cohort of 269 postmenopausal patients, 63 met the study-defined cardiac dysfunction endpoint. Adding SII or SIRI improved internal AUC from 0.633 to 0.745 or 0.733, respectively; both markers were independently associated with the endpoint. The paper reports covariate-adjusted regression, sensitivity analyses, five-fold cross-validation with fold-wise preprocessing, and calibration/decision analyses. Small cohort, 63 events, retrospective operational endpoint, residual selection bias, and no external validation prevent claims of clinical implementation or validated prediction.
Technology: Baseline SII/SIRI were evaluated in logistic prediction models with stratified five-fold out-of-fold predictions; an exploratory machine-learning analysis also used an SVM to classify overlapping endpoint components.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Baseline SII/SIRI were evaluated in logistic prediction models with stratified five-fold out-of-fold predictions; an exploratory machine-learning analysis also used an SVM to classify overlapping endpoint components.
- Test and result
- In a single-center cohort of 269 postmenopausal patients, 63 met the study-defined cardiac dysfunction endpoint. Adding SII or SIRI improved internal AUC from 0.633 to 0.745 or 0.733, respectively; both markers were independently associated with the endpoint.
- Limitation / still unknown
- The paper reports covariate-adjusted regression, sensitivity analyses, five-fold cross-validation with fold-wise preprocessing, and calibration/decision analyses. Small cohort, 63 events, retrospective operational endpoint, residual selection bias, and no external validation prevent claims of clinical implementation or validated prediction.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1888328/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary source full text Methods and Results; version/date checked against bibliographic record..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.